Strive priced a $630 million offering of a new preferred-share series on October 15, 2026. The useful distinction for investors is between the headline fundraising amount, the cash left after costs and the conditional dividend terms—not simply the advertised 15% rate.
The issuer announcement scheduled settlement for October 20, subject to closing conditions. This is an initial offering of SATS preferred stock, not the first flotation of Strive’s already-listed common shares.
What the offering documents establish
| Item | Verified detail | Source |
|---|---|---|
| Issuer and stage | Strive; priced October 15, 2026; settlement expected October 20, subject to conditions. | Pricing release |
| Security and venue | 15.00% Series A Perpetual SATS Preferred Stock; Nasdaq Global Market listing applied for under SATS. | Final prospectus |
| Price and issue composition | 7,000,000 newly issued preferred shares at $90 each; not an existing-holder OFS. | Final prospectus |
| Gross and estimated net proceeds | $630 million gross; $609 million after underwriting but before other expenses; approximately $608.15 million net after estimated offering expenses. | Final prospectus |
| Par versus stated amount | $0.001 par value; $100 stated amount and initial liquidation preference. These are different measures. | Final prospectus |
| Use of proceeds | General corporate purposes, including possible Bitcoin-related purchases, working capital and other disclosed uses; allocation is not proof of completed spending. | Final prospectus |
| Retail application details | No Indian-style bidding window or category-specific lot/minimum application verified in the checked documents. | Final prospectus |
| Listing and registrar | If Nasdaq approves listing, trading expected within 30 days of first issuance; initial transfer agent, registrar and paying agent: VStock Transfer, LLC. | Final prospectus |
Why $630 million is not the cash available to deploy
The calculation is 7 million shares × $90 = $630 million gross. Underwriting discounts total $21 million, leaving $609 million before other expenses. The final prospectus then estimates $608.15 million net. None of those figures establishes that the proceeds have already been received or invested.
A dividend rate is not a guaranteed return
The 15% annual accumulation rate applies to the $100 stated amount: $15 per share annually. Cash payment requires a board declaration and legally available funds. Scheduled business-day payments begin November 9, subject to those conditions. The rate is not a promise of investment performance or protection against a falling share price.
What to watch next is confirmation of settlement and Nasdaq approval. The checked prospectus says no public SATS market yet existed; this report does not claim trading has started.
Related reading: City Therapeutics: gross versus net IPO proceeds.
Recorded source observation: (UTC). This is a source-check timestamp, not a market quote or a new article update.